In one paragraphArticle in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Iris E Glykofridis *Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.ORCID 0000-0003-1829-2403 Marleen Dekker *Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.ORCID 0000-0001-8033-5692 Chantal Stoepker *Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
Thomas W van Ravesteyn *Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
Yvonne TiersmaDivision of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.ORCID 0000-0001-7691-654X Cédric G van der HamDivision of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.ORCID 0009-0007-0542-6819 Beaunelle de BruijnDivision of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.ORCID 0000-0001-5488-3695 Salma EbrahimDivision of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.ORCID 0009-0002-5881-0965 Renée X de MenezesBiostatistics Centre, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
Esmee KasteleijnDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam 3015 GD, The Netherlands.ORCID 0009-0005-7669-631X Frans VerheijenDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam 3015 GD, The Netherlands.
Tjakko J van HamDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam 3015 GD, The Netherlands.ORCID 0000-0002-2175-8713 Hein Te RieleDivision of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.ORCID 0000-0003-0255-4042 Funding
Dutch Cancer Society 10645Dutch Cancer Society 14469Dutch Research Council TTW 1488
6 · The paper itselfAbstract
Lynch syndrome (LS) is a genetic predisposition to mainly colorectal and endometrial cancer due to heterozygous disruptive germline mutations in the DNA mismatch-repair (MMR) genes
Indexed as
Colorectal Neoplasms, Hereditary NonpolyposisAnimalsDNA-Binding ProteinsDNA Mismatch RepairFemaleGenetic Predisposition to DiseaseGerm-Line MutationHumansMiceMismatch Repair Endonuclease PMS2MutL Protein Homolog 1MutS Homolog 2 ProteinDNA-Binding ProteinsMismatch Repair Endonuclease PMS2MutL Protein Homolog 1MutS Homolog 2 ProteinPMS2 protein, humanDNA mismatch repairfunctional assayLynch syndromeVUS
Identifiers
PMID41543911
PMCPMC12818420
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390